PartnerFacts
Data last updated: Oct 23, 2026, 5:45 PM ETLatest filing: Oct 22, 2026Now: Oct 24, 2026, 5:37 AM ET

Sponsor Check › Person

RN
No photo found yet (own website and image search run after this page is viewed)

Robert Nelsen

Named as an officer, director or promoter on SEC Form D filings · WA, IL, NJ, MA, CA, NY, CO · Aug 17, 2011 → Sep 7, 2021

39deals (issuers)
$13.51Breported sold
1,308investors
88Form D filings
2011–2021years on file
Follow this personLook further ↓PDF

Data last updated Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 3:03 AM ET · SEC enforcement last checked: covered by the index scan as of Oct 24, 2026, 2:50 AM ET

The short version

Robert Nelsen is listed as an executive officer, director, and promoter on 88 SEC Form D filings by 39 issuers between May 2009 and Aug 2026. Largest by amount reported sold: ARCH Venture Fund XII, L.P. (Chicago, IL — pooled investment fund — 2022; $2.81B reported sold to 103 investors), ARCH Venture Fund XI, L.P. (Chicago, IL — pooled investment fund — 2020–2021; $1.85B reported sold to 93 investors), GRAIL, Inc. (Menlo Park, CA — biotechnology — 2017–2020; $1.21B reported sold to 59 investors), Juno Therapeutics, Inc. (Seattle, WA — biotechnology — 2013–2017; $898.5M reported sold to 34 investors), Sana Biotechnology, Inc. (Seattle, WA — biotechnology — 2020; $821.1M reported sold to 40 investors) and 34 more (all listed below).

What this means That is a lot of deals — 39 separate companies raised money with this person listed as executive officer, director, and promoter, over about 17 years. Across those companies the filings report $13.51B sold in total.

Listed alongside Kristina Burow (33 shared filings), Mark McDonnell (16 shared filings), Keith Crandell (15 shared filings), Richard Klausner (13 shared filings), Hans Bishop (11 shared filings) and 235 others.

What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Robert. Each name links to their own page.

The issuers belong to 2 sponsor groups: Arch Venture (10 issuers, $6.74B reported sold, 2014–2026) and Maveron (16 issuers, $544.5M reported sold, 2013–2022).

What this means This person is listed across more than one sponsor team; each group page shows that team's full track record.

Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — 13 bankruptcy cases matching the name listed in Key records below.

What this means 13 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.

We compared the newest 50 of 88 public filings for Robert Nelsen and found 9 differences, 1 worth asking the sponsor about: 8 Form Ds were filed more than 15 days after the first sale; and more below.

What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.

What the community is saying

Community search for Robert Nelsen has not run yet — it is #13,098 of 19,354 in line; searches run around the clock at the hosts' allowed rate. Searched so far: 32 names.

Community comments are quoted as written by their authors. Sources searched: BiggerPockets forums (via DuckDuckGo, Brave, Bing and BiggerPockets search) and Reddit (search feed + public archive).

Key records

Five things investors ask first. Items still in human review are counted, not shown.

1. Lawsuits

None found in sources searched — federal courts (CourtListener / RECAP), checked Oct 24, 2026

What was searched

Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts State courts: not covered (one-tap state court links under Look further). PACER: not searched. · Last checked Oct 24, 2026, 3:03 AM ET.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

2. Regulatory actions

None found in sources searched — SEC enforcement releases (index scan as of Oct 24, 2026, 2:50 AM ET) · state securities regulators: AZ, CA, DE, TX, WA (crawled Oct 23, 2026)

What was searched

SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — Searched SEC litigation releases and administrative proceedings (1995→ / 2007→) (30,205 records as of Oct 24, 2026, 2:50 AM ET) — nothing matched Robert Nelsen..

State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states are not covered.

3. Bankruptcies

13 cases: 1 open, 12 closed (disposition not in docket feed)

Robert J Nelsen open
United States Bankruptcy Court, M.D. Florida · No. 8:25-bk-05511 · Filed Aug 5, 2025
Role of Robert J Nelsen: Debtor · Outcome: Open — no termination date on the docket (bulk snapshot 2026-09-30) Docket on CourtListener ↗
same full name (a name found in 20 federal dockets); 2 people with this name in Form D filings; court in FL (not a filing state)
Robert Nelsen and Geraldine Roche Nelsen closed
United States Bankruptcy Court, E.D. California · No. 11-45725 · Filed Oct 28, 2011 · Closed Feb 24, 2012
Role of Robert Nelsen and Geraldine Roche Nelsen: Debtor · Outcome: Case closed 2012-02-24 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 20 federal dockets); 2 people with this name in Form D filings; court in the person's filing state (CA)
Robert J Nelsen closed
United States Bankruptcy Court, D. New Jersey · No. 10-44301 · Filed Nov 3, 2010 · Closed Mar 11, 2011
Role of Robert J Nelsen: Debtor · Outcome: Case closed 2011-03-11 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 20 federal dockets); 2 people with this name in Form D filings; court in the person's filing state (NJ)
Robert W Nelsen closed
United States Bankruptcy Court, D. Minnesota · No. 09-48699 · Filed Dec 22, 2009 · Closed Apr 14, 2010
Role of Robert W Nelsen: Debtor · Outcome: Case closed 2010-04-14 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 20 federal dockets); 2 people with this name in Form D filings; court in MN (not a filing state)
ROBERT NELSEN and TERESA NELSEN closed
United States Bankruptcy Court, D. Nevada · No. 08-21466 · Filed Sep 30, 2008 · Closed Jun 24, 2010
Role of ROBERT NELSEN and TERESA NELSEN: Debtor · Outcome: Case closed 2010-06-24 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 20 federal dockets); 2 people with this name in Form D filings; court in NV (not a filing state)
Robert A. Nelsen closed
United States Bankruptcy Court, S.D. California · No. 06-03819 · Filed Dec 5, 2006 · Closed Jul 8, 2011
Role of Robert A. Nelsen: Debtor · Outcome: Case closed 2011-07-08 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 20 federal dockets); 2 people with this name in Form D filings; court in the person's filing state (CA)
ROBERT NELSEN closed
United States Bankruptcy Court, D. Nevada · No. 03-25488 · Filed Dec 18, 2003 · Closed Oct 7, 2004
Role of ROBERT NELSEN: Debtor · Outcome: Case closed 2004-10-07 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 20 federal dockets); 2 people with this name in Form D filings; court in NV (not a filing state)
Robert Nelsen closed
United States Bankruptcy Court, E.D. New York · No. 1-02-16494 · Filed May 21, 2002 · Closed Apr 22, 2003
Role of Robert Nelsen: Debtor · Outcome: Case closed 2003-04-22 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 20 federal dockets); 2 people with this name in Form D filings; court in the person's filing state (NY)
ROBERT W. NELSEN and MARJORIE A. NELSEN closed
United States Bankruptcy Court, D. Nevada · No. 98-31996 · Filed Jul 17, 1998 · Closed Nov 4, 1998
Role of ROBERT W. NELSEN and MARJORIE A. NELSEN: Debtor · Outcome: Case closed 1998-11-04 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 20 federal dockets); 2 people with this name in Form D filings; court in NV (not a filing state)
Robert L Nelsen and Carol A Nelsen closed
United States Bankruptcy Court, C.D. California · No. 1:98-bk-18115 · Filed Jun 10, 1998 · Closed Sep 30, 1998
Role of Robert L Nelsen and Carol A Nelsen: Debtor · Outcome: Case closed 1998-09-30 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 20 federal dockets); 2 people with this name in Form D filings; court in the person's filing state (CA)
Robert L. Nelsen and Audrey B. Nelsen closed
United States Bankruptcy Court, D. New Mexico · No. 97-12163 · Filed Apr 15, 1997 · Closed Jul 31, 1997
Role of Robert L. Nelsen and Audrey B. Nelsen: Debtor · Outcome: Case closed 1997-07-31 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 20 federal dockets); 2 people with this name in Form D filings; court in NM (not a filing state)
Robert Nelsen and Tina Nelsen closed
United States Bankruptcy Court, S.D. Iowa · No. 95-00997 · Filed Apr 7, 1995 · Closed Jul 17, 1995
Role of Robert Nelsen and Tina Nelsen: Debtor · Outcome: Case closed 1995-07-17 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 20 federal dockets); 2 people with this name in Form D filings; court in IA (not a filing state)
Robert G. Nelsen and Elizabeth Ann Nelsen closed
United States Bankruptcy Court, D. Oregon · No. 92-36503 · Filed Sep 30, 1992 · Closed Jun 11, 1996
Role of Robert G. Nelsen and Elizabeth Ann Nelsen: Debtor · Outcome: Case closed 1996-06-11 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 20 federal dockets); 2 people with this name in Form D filings; court in OR (not a filing state)
What was searched

Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not covered (one-tap state court links under Look further). PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 3:03 AM ET.

Court records show docket facts only; we never restate allegations as facts. Outcome wording comes from the docket feed; where it does not state a disposition we say so.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

4. Differences between public sources

Comparisons cover issuers and sponsor groups — see the issuer pages under Deals

9 differences found between the filings for Robert Nelsen — 1 worth asking about (compared the newest 50 of 88 filings on Oct 24, 2026; older filings not covered)

Worth asking · Oct 14, 2016 – Jan 3, 2023

8 Form Ds were filed more than 15 days after the first sale

Form D filed 847 days after the first sale — Neumora Therapeutics, Inc. · Form D filed 75 days after the first sale — National Resilience, Inc. · Form D filed 499 days after the first sale — Sana Biotechnology, Inc. · Form D filed 633 days after the first sale — Sana Biotechnology, Inc. · Form D filed 62 days after the first sale — Insitro, Inc. · and 3 more

What this means Late notices are common and carry no penalty by themselves. A pattern of late paperwork is worth asking the sponsor about.

Form D · Jan 3, 2023 ↗Neumora Therapeutics, Inc. — PartnerFacts page ↗Form D · Jan 6, 2021 ↗National Resilience, Inc. — PartnerFacts page ↗
Sources
Note · Oct 20, 2015 – Apr 1, 2022

10 offerings changed their target amount between filings

Offering amount changed between filings — ARCH Venture Fund XII, L.P. · Offering amount changed between filings — ARCH Venture Fund XI, L.P. · Offering amount changed between filings — GRAIL, Inc. · Offering amount changed between filings — ARCH Venture Fund X Overage, L.P. · Offering amount changed between filings — ARCH Venture Fund X, L.P. · and 5 more

What this means Targets change as deals grow or shrink. Ask whether later money has the same terms.

Form D (earlier) · Feb 3, 2022 ↗Form D/A (later) · Apr 1, 2022 ↗ARCH Venture Fund XII, L.P. — PartnerFacts page ↗Form D (earlier) · Nov 18, 2020 ↗
Sources
Note · Jun 29, 2015 – Oct 31, 2024

21 offerings have no amendment in the last 12 months and may still be open

No amendment in the last 12 months on an offering that may still be open — Seaport Therapeutics, Inc. (latest filing Oct 31, 2024) · No amendment in the last 12 months on an offering that may still be open — ARCH Venture Fund XII, L.P. (latest filing Apr 1, 2022) · No amendment in the last 12 months on an offering that may still be open — Apex Neuro Holdings, Inc. (latest filing Mar 23, 2022) · No amendment in the last 12 months on an offering that may still be open — Nutcracker Therapeutics, Inc. (latest filing Sep 7, 2021) · No amendment in the last 12 months on an offering that may still be open — Medical Creations, Inc. (latest filing Jun 22, 2021) · and 16 more

What this means SEC rules expect a yearly amendment while an offering is still going. Ask the sponsor which of these raises have closed.

Form D · Oct 31, 2024 ↗Seaport Therapeutics, Inc. — PartnerFacts page ↗Form D/A · Apr 1, 2022 ↗ARCH Venture Fund XII, L.P. — PartnerFacts page ↗
Sources
Note · Jul 14, 2015 – Mar 17, 2016

Robert Nelsen is written 2 different ways on the filings

listed as "Robert Nelsen" on 39 filings (from Jul 14, 2015), and "Robert T. Nelsen" on 14 filings (from Mar 17, 2016).

What this means Same person, written differently — a middle name or suffix left off, or spelled another way. It is normal, but check that the full legal name matches your subscription documents.

Form D · Jul 14, 2015 ↗Form D · Mar 17, 2016 ↗Robert Nelsen — PartnerFacts page ↗
Sources
Note · Dec 1, 2016 – Mar 27, 2018

Industry group changed between filings — Unity Biotechnology, Inc.

"Biotechnology" (Dec 1, 2016 to Aug 21, 2017); then "Pharmaceuticals" (Mar 27, 2018).

What this means The issuer described its business differently on different forms. Often it is just a different box ticked; sometimes the deal itself changed. Ask which business your money is in.

Form D · Dec 1, 2016 ↗Form D · Mar 27, 2018 ↗Unity Biotechnology, Inc. — PartnerFacts page ↗
Sources
Note · Oct 4, 2022

Same name, different state: "Robert Nelsen" (MN) is a separate record

This page covers filings where the address state is WA or IL or NJ or MA or CA or NY or CO. A separate record, "Robert Nelsen" with address state MN, is listed on 1 filing — most recently by High Plains Partners, LLC (Oct 4, 2022). The two records do not overlap in time: this page runs Aug 17, 2011 to Sep 7, 2021; the other has one filing dated Oct 4, 2022.

What this means Could be the same person who moved, or two people with the same name. We keep them apart until a filing ties them together. Check both pages before you decide.

Robert Nelsen (MN) — PartnerFacts page ↗Form D · Oct 4, 2022 ↗High Plains Partners, LLC — PartnerFacts page ↗Robert Nelsen (WA,IL,NJ,MA,CA,NY,CO) — this page ↗
Sources
Note · Oct 20, 2015 – May 15, 2017

Address moved from Carlsbad, CA to Westlake Village, CA — Sienna Biopharmaceuticals, Inc.

The people listed on the Oct 20, 2015 filing give Carlsbad, CA; on the May 15, 2017 filing they give Westlake Village, CA.

What this means Businesses move; this just shows the two places and dates. If you were told one city and the forms say another, ask which is current.

Form D · Oct 20, 2015 ↗Form D/A · May 15, 2017 ↗Sienna Biopharmaceuticals, Inc. — PartnerFacts page ↗
Sources
Note · Jul 14, 2015 – Aug 31, 2026

Robert Nelsen is listed with 6 different address states: WA, IL, CA, MA, NY, CO

WA on 8 filings (Jul 14, 2015 to Oct 16, 2024); IL on 13 filings (Mar 17, 2016 to Aug 31, 2026); CA on 22 filings (Dec 1, 2016 to Sep 7, 2021); MA on 6 filings (Jan 17, 2018 to Oct 31, 2024); NY on 3 filings (Nov 8, 2019 to Mar 23, 2022); CO on 1 filing (Jun 22, 2021).

What this means The address on a Form D is usually the company's, not the person's home, so this often just reflects different companies. It can also mean a move. Nothing wrong by itself.

Form D · Jul 14, 2015 ↗Form D · Mar 17, 2016 ↗Form D · Dec 1, 2016 ↗Form D · Jan 17, 2018 ↗
Sources
Note · Jul 14, 2015 – Oct 5, 2017

Reported revenue range changed between filings — Juno Therapeutics, Inc.

"No Revenues" (Jul 14, 2015); then "$5,000,001 - $25,000,000" (Jul 6, 2016); then "$25,000,001 - $100,000,000" (Oct 5, 2017).

What this means This is the size band the issuer picks for itself on the form. A change can mean the business grew or shrank — or that it chose not to say. Ask for current numbers.

Form D · Jul 14, 2015 ↗Form D/A · Jul 6, 2016 ↗Form D · Oct 5, 2017 ↗Juno Therapeutics, Inc. — PartnerFacts page ↗
Sources
What is compared

What is compared: every Form D and D/A we hold for this subject, side by side — filing dates vs. first-sale dates (the 15-day rule), amendment timing on open offerings (the yearly-amendment expectation), amounts sold, investor counts, offering amounts and minimums across amendments, industry and size bands, addresses, how each person's name and role is written, paid sellers' CRD numbers, and (for groups) where the member companies were formed and sit. Everything is as filed by the issuer; the SEC does not check it. Differences are common and usually have ordinary explanations — we show both values, the dates, and the source so you can ask. We compared the newest 50 of 88 filings (work cap); older filings are not covered here. As of Oct 24, 2026.

5. Money to insiders

3 of 70 offerings report sales commissions totalling $4,264,182; 1 reports finder's fees totalling $4,739; 3 report proceeds to related persons totalling $1,140,000. (includes amounts the issuer reported as estimates)

Offering (latest filing)Sales commissionsFinder's feesTo insidersPaid to sell itSource
Aug 31, 2026 D
ARCH Venture Fund XIV, L.P.
File 021-595988
$0$0$0
The General Partner (or its designee) will receive a fee for management services payable by the Issuer quarterly in advance as specified in the Issuer's partnership agreement.
None listed on this filingEDGAR ↗
Oct 31, 2024 D
Seaport Therapeutics, Inc.
File 021-528276
$0$0$0None listed on this filingEDGAR ↗
Oct 16, 2024 D
RIPPL Care, Inc.
File 021-526980
$0$0$0None listed on this filingEDGAR ↗
Feb 1, 2024 D
ARCH Venture Fund XIII, L.P.
File 021-504109
$0$0$0
The General Partner (or its designee) will receive a fee for management services payable by the Issuer quarterly in advance as specified in the Issuer's partnership agreement.
None listed on this filingEDGAR ↗
Jan 3, 2023 D
Neumora Therapeutics, Inc.
File 021-469477
$0$0$0None listed on this filingEDGAR ↗
Apr 1, 2022 D/A
ARCH Venture Fund XII, L.P.
File 021-432243
$0$0$0
The General Partner (or its designee) will receive a fee for management services payable by the Issuer quarterly in advance as specified in the Issuer's partnership agreement.
None listed on this filingEDGAR ↗
Mar 23, 2022 D
Apex Neuro Holdings, Inc.
File 021-438604
$0$0$0
Other than the payment of salaries and other compensation and benefits and reimbursement of expenses, no officer, director, partner, manager or promoter will receive any payments from the proceeds of this offering.
None listed on this filingEDGAR ↗
Sep 7, 2021 D
Nutcracker Therapeutics, Inc.
File 021-412462
$0$0$0None listed on this filingEDGAR ↗
Jun 22, 2021 D
Medical Creations, Inc.
File 021-403712
$0$0$350,000 (est.)None listed on this filingEDGAR ↗
Jan 28, 2021 D/A
ARCH Venture Fund XI, L.P.
File 021-380955
$0$0$0
The General Partner (or its designee) will receive a fee for management services payable by the Issuer quarterly in advance based on a percentage of aggregate subscriptions to the Issuer as specified in the Issuer's partnership agreement.
None listed on this filingEDGAR ↗
Jan 6, 2021 D
National Resilience, Inc.
File 021-385393
$0$0$0None listed on this filingEDGAR ↗
Jun 26, 2020 D
Sana Biotechnology, Inc.
File 021-369781
$0$0$0None listed on this filingEDGAR ↗
Jun 26, 2020 D
Sana Biotechnology, Inc.
File 021-369787
$0$0$0None listed on this filingEDGAR ↗
May 27, 2020 D
Insitro, Inc.
File 021-367759
$0$0$0None listed on this filingEDGAR ↗
May 19, 2020 D
Nutcracker Therapeutics, Inc.
File 021-367232
$0$0$0None listed on this filingEDGAR ↗
May 8, 2020 D
Vir Biotechnology, Inc.
File 021-366580
$0$0$0None listed on this filingEDGAR ↗
May 8, 2020 D
Vir Biotechnology, Inc.
File 021-366581
$0$0$0None listed on this filingEDGAR ↗
May 7, 2020 D/A
GRAIL, Inc.
File 021-355443
$0$0$0None listed on this filingEDGAR ↗
Nov 26, 2019 D/A
Apex Neuro Holdings, Inc.
File 021-352962
$0$0$0
Other than the payment of salaries and other compensation and benefits and reimbursement of expenses, no officer, director, partner, manager or promoter will receive any payments from the proceeds of this offering.
None listed on this filingEDGAR ↗
Oct 25, 2019 D/A
ARCH Venture Fund X, L.P.
File 021-324494
$0$0$0 (est.)
The General Partner (or its designee) will receive a fee for management services payable by the Issuer quarterly in advance based on a percentage of aggregate subscriptions to the Issuer as specified in the Issuer's partnership agreement.
None listed on this filingEDGAR ↗
Oct 25, 2019 D/A
ARCH Venture Fund X Overage, L.P.
File 021-324501
$0$0$0 (est.)
The General Partner (or its designee) will receive a fee for management services payable by the Issuer quarterly in advance based on a percentage of aggregate investments made by the Issuer as specified in the Issuer's partnership agreement.
None listed on this filingEDGAR ↗
Mar 26, 2019 D/A
Beam Therapeutics Inc.
File 021-318897
$0$0$0None listed on this filingEDGAR ↗
Mar 26, 2019 D
Beam Therapeutics Inc.
File 021-335722
$0$0$0None listed on this filingEDGAR ↗
Aug 1, 2018 D
Gossamer Bio, Inc.
File 021-318226
$0$0$0None listed on this filingEDGAR ↗
Jun 29, 2018 D
Vir Biotechnology, Inc.
File 021-315844
$0$0$0None listed on this filingEDGAR ↗
May 25, 2018 D
GRAIL, Inc.
File 021-313322
$0$0$0None listed on this filingEDGAR ↗
Mar 27, 2018 D
Unity Biotechnology, Inc.
File 021-308697
$0$0$0None listed on this filingEDGAR ↗
Feb 9, 2018 D/A
Syros Pharmaceuticals, Inc.
File 021-303459
$0$0$0None listed on this filingEDGAR ↗
Jan 19, 2018 D
Gossamer Bio, Inc.
File 021-303729
$0$0$0None listed on this filingEDGAR ↗
Jan 19, 2018 D
Gossamer Bio, Inc.
File 021-303730
$0$0$0None listed on this filingEDGAR ↗
Jan 11, 2018 D/A
GRAIL, Inc.
File 021-282443
$2,241,721 (est.)$0$0Goldman, Sachs & Co. BrokerCheck CRD 361 ↗
ABG, LLC BrokerCheck CRD 167190 ↗		EDGAR ↗
Oct 5, 2017 D
Juno Therapeutics, Inc.
File 021-296114
$0$0$0None listed on this filingEDGAR ↗
Aug 21, 2017 D/A
Unity Biotechnology, Inc.
File 021-275461
$0$0$0None listed on this filingEDGAR ↗
Jun 29, 2017 D/A
Juno Therapeutics, Inc.
File 021-243722
$0$0$0None listed on this filingEDGAR ↗
Jun 13, 2017 D
Arivale Inc.
File 021-288607
$0$0$0None listed on this filingEDGAR ↗
May 15, 2017 D/A
Sienna Biopharmaceuticals, Inc.
File 021-249771
$0$0$0None listed on this filingEDGAR ↗
May 15, 2017 D
Sienna Biopharmaceuticals, Inc.
File 021-286730
$0$0$0None listed on this filingEDGAR ↗
Nov 18, 2016 D/A
ARCH Venture Fund IX, L.P.
File 021-259517
$0$0$0 (est.)
The General Partner (or its designee) will receive a fee for management services payable by the Issuer quarterly in advance based on a percentage of aggregate subscriptions to the Issuer as specified in the Issuer's partnership agreement.
None listed on this filingEDGAR ↗
Nov 18, 2016 D
ARCH Venture Fund IX Overage, L.P.
File 021-274831
$0$0$0None listed on this filingEDGAR ↗
Dec 15, 2015 D
SAPPHIRE ENERGY, INC.
File 021-253073
$0 (est.)$0 (est.)$0 (est.)None listed on this filingEDGAR ↗
Mar 6, 2015 D
ARCH Venture Fund VIII Overage, L.P.
File 021-235405
$0$0$0None listed on this filingEDGAR ↗
Oct 24, 2014 D
Syros Pharmaceuticals, Inc.
File 021-227114
$0$0$0None listed on this filingEDGAR ↗
Aug 27, 2014 D/A
ARCH Venture Fund VIII, L.P.
File 021-216149
$0$0$0
The General Partner (or its designee) will receive a fee for management services payable by the Issuer quarterly in advance based on a percentage of aggregate subscriptions to the Issuer as specified in the Issuer's partnership agreement.
None listed on this filingEDGAR ↗
Aug 14, 2014 D
Juno Therapeutics, Inc.
File 021-222931
$0$0$0None listed on this filingEDGAR ↗
Jul 23, 2014 D
Faraday Pharmaceuticals, Inc.
File 021-221669
$0$0$0None listed on this filingEDGAR ↗
Jul 2, 2014 D
Bellerophon Therapeutics, Inc.
File 021-220220
$0$0$0None listed on this filingEDGAR ↗
May 8, 2014 D
Juno Therapeutics, Inc.
File 021-217030
$0$0$0None listed on this filingEDGAR ↗
Mar 24, 2014 D
Sage Therapeutics, Inc.
File 021-214112
$0$0$0None listed on this filingEDGAR ↗
Feb 21, 2014 D
Bellerophon Therapeutics, Inc.
File 021-212315
$0$0$0None listed on this filingEDGAR ↗
Jan 21, 2014 D
Sage Therapeutics, Inc.
File 021-210441
$0$0$0None listed on this filingEDGAR ↗
Dec 26, 2013 D
Juno Therapeutics, Inc.
File 021-208784
$0$0$0None listed on this filingEDGAR ↗
Aug 13, 2013 D
FATE THERAPEUTICS INC
File 021-201262
$0$0$0None listed on this filingEDGAR ↗
Jul 15, 2013 D
Unity Biotechnology, Inc.
File 021-199666
$0$0$0None listed on this filingEDGAR ↗
Apr 22, 2013 D
Syros Pharmaceuticals, Inc.
File 021-195350
$0$0$0None listed on this filingEDGAR ↗
Nov 27, 2012 D
NeurogesX Inc
File 021-187469
$0$0$0None listed on this filingEDGAR ↗
Aug 21, 2012 D
FATE THERAPEUTICS INC
File 021-183005
$0$0$0None listed on this filingEDGAR ↗
Mar 29, 2012 D
NeurogesX Inc
File 021-175897
$0$0$0None listed on this filingEDGAR ↗
Feb 8, 2012 D
NeurogesX Inc
File 021-173081
$0$0$0
Funds to be used for working capital.
None listed on this filingEDGAR ↗
Nov 22, 2011 D
AGIOS PHARMACEUTICALS INC
File 021-169115
$0$0$0None listed on this filingEDGAR ↗
Sep 15, 2011 D
KYTHERA BIOPHARMACEUTICALS INC
File 021-165882
$1,012,000$4,739$0Leerink Swann LLC BrokerCheck CRD 39011 ↗EDGAR ↗
Aug 17, 2011 D
NeurogesX Inc
File 021-164574
$0$0$0
Funds to be used for working capital.
None listed on this filingEDGAR ↗
Aug 3, 2011 D
NeurogesX Inc
File 021-163898
$1,010,461$0$0
Funds to be used for working capital.
Leerink Swann LLC BrokerCheck CRD 39011 ↗EDGAR ↗
Apr 20, 2011 D/A
FATE THERAPEUTICS INC
File 021-117892
$0$0$0None listed on this filingEDGAR ↗
Apr 20, 2011 D
FATE THERAPEUTICS INC
File 021-158650
$0$0$0None listed on this filingEDGAR ↗
Aug 6, 2010 D
Kilimanjaro Energy, Inc.
File 021-146056
$0$0$0None listed on this filingEDGAR ↗
Aug 6, 2010 D
Kilimanjaro Energy, Inc.
File 021-146058
$0$0$600,000
To be used for the payment of the annual salaries of the issuer's executive officers.
None listed on this filingEDGAR ↗
Apr 26, 2010 D
AGIOS PHARMACEUTICALS INC
File 021-141089
$0$0$0None listed on this filingEDGAR ↗
Nov 23, 2009 D
Receptos, Inc.
File 021-131445
$0$0$190,000 (est.)
This is the sum of the budgeted salaries for the applicable executive officers for the next 12 months.
None listed on this filingEDGAR ↗
Oct 2, 2009 D/A
IKARIA HOLDINGS INC
File 021-102325
$0$0$0None listed on this filingEDGAR ↗
May 5, 2009 D
Unity Biotechnology, Inc.
File 021-130673
$0$0$0None listed on this filingEDGAR ↗
How this is counted

Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.

Counted across every filing this person is listed on (latest filing per offering, per issuer).

Deals 39

Every issuer that named Robert Nelsen on a Form D, newest first. A Form D is the notice a company files after it starts selling a private investment.

AV
Pooled Investment Fund · group: Arch Venture

ARCH Venture Fund XIV, L.P.

Chicago, IL · Aug 31, 2026
  • Aug 31, 2026 · D · $0 sold of $3,000,000,000 · 0 investors · min. No minimum reported · role: Executive Officer (Managing Director of the GP LLC) EDGAR ↗

No sales reported yet as of the latest filing. Robert is listed as executive officer.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

ST
Biotechnology

Seaport Therapeutics, Inc.

Boston, MA · Oct 31, 2024
  • Oct 31, 2024 · D · $225,899,940 sold of $225,999,937 · 33 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $225.9M from 33 investors (100% of the $226M target) as of the latest filing. Robert is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

RC
Other Health Care

RIPPL Care, Inc.

Seattle, WA · Oct 16, 2024
  • Oct 16, 2024 · D · $23,000,000 sold of $23,000,000 · 9 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $23M from 9 investors (100% of the $23M target) as of the latest filing. Robert is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AV
Pooled Investment Fund · group: Arch Venture

ARCH Venture Fund XIII, L.P.

Chicago, IL · Feb 1, 2024
  • Feb 1, 2024 · D · $0 sold of $3,000,000,000 · 0 investors · min. No minimum reported · role: Executive Officer (Managing Director of the GP LLC) EDGAR ↗

No sales reported yet as of the latest filing. Robert is listed as executive officer.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

NT
Biotechnology

Neumora Therapeutics, Inc.

Watertown, MA · Jan 3, 2023
  • Jan 3, 2023 · D · $474,356,988 sold of $474,356,988 · 124 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $474.4M from 124 investors (100% of the $474.4M target) as of the latest filing. Robert is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AV
Pooled Investment Fund · group: Arch Venture

ARCH Venture Fund XII, L.P.

Chicago, IL · Feb 3, 2022 → Apr 1, 2022 · 2 filings
  • Apr 1, 2022 · D/A · $2,810,000,000 sold of $2,910,000,000 · 103 investors · min. No minimum reported · role: Executive Officer (Managing Director of the GP LLC) EDGAR ↗
  • Feb 3, 2022 · D · $0 sold of $2,500,000,000 · 0 investors · min. No minimum reported · role: Executive Officer (Managing Director of the GP LLC) EDGAR ↗

Raised $2.81B from 103 investors (97% of the $2.91B target) as of the latest filing. Robert is listed as executive officer on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AN
Other

Apex Neuro Holdings, Inc.

Brooklyn, NY · Nov 8, 2019 → Mar 23, 2022 · 3 filings
  • Mar 23, 2022 · D · $4,000,000 sold of $10,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Nov 26, 2019 · D/A · $20,000,004 sold of $20,000,004 · 5 investors · min. No minimum reported · role: Director EDGAR ↗
  • Nov 8, 2019 · D · $18,000,005 sold of $20,000,004 · 4 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $20M from 5 investors (100% of the $10M target) as of the latest filing. Robert is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other / 506(b) (18,678 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

NT
Biotechnology

Nutcracker Therapeutics, Inc.

Emeryville, CA · May 19, 2020 → Sep 7, 2021 · 2 filings
  • Sep 7, 2021 · D · $144,499,977 sold of $199,999,994 · 14 investors · min. No minimum reported · role: Director EDGAR ↗
  • May 19, 2020 · D · $13,999,990 sold of $60,036,840 · 5 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $144.5M from 14 investors (72% of the $200M target) as of the latest filing. Robert is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

MC
Other Health Care

Medical Creations, Inc.

Denver, CO · Jun 22, 2021
  • Jun 22, 2021 · D · $7,722,649 sold of $15,000,000 · 7 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $7.72M from 15 investors (51% of the $15M target) as of the latest filing. Robert is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AV
Pooled Investment Fund · group: Arch Venture

ARCH Venture Fund XI, L.P.

Chicago, IL · Nov 18, 2020 → Jan 28, 2021 · 2 filings
  • Jan 28, 2021 · D/A · $1,850,000,000 sold of $1,850,000,000 · 93 investors · min. No minimum reported · role: Executive Officer (Managing Director of the GP LLC) EDGAR ↗
  • Nov 18, 2020 · D · $0 sold of $1,500,000,000 · 0 investors · min. No minimum reported · role: Executive Officer (Managing Director of the GP LLC) EDGAR ↗

Raised $1.85B from 93 investors (100% of the $1.85B target) as of the latest filing. Robert is listed as executive officer on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

NR
Biotechnology

National Resilience, Inc.

La Jolla, CA · Jan 6, 2021
  • Jan 6, 2021 · D · $755,000,062 sold of $755,000,062 · 85 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $755M from 85 investors (100% of the $755M target) as of the latest filing. Robert is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

SB
Biotechnology

Sana Biotechnology, Inc.

Seattle, WA · Jun 26, 2020 → Jun 26, 2020 · 2 filings
  • Jun 26, 2020 · D · $821,097,521 sold of $821,097,521 · 40 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 26, 2020 · D · $45,850,000 sold of $45,850,000 · 8 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $821.1M from 40 investors (100% of the $821.1M target) as of the latest filing. Robert is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

I
Biotechnology

Insitro, Inc.

South San Francisco, CA · May 27, 2020
  • May 27, 2020 · D · $143,210,951 sold of $143,210,951 · 26 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $143.2M from 26 investors (100% of the $143.2M target) as of the latest filing. Robert is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

VB
Biotechnology

Vir Biotechnology, Inc.

San Francisco, CA · Jun 29, 2018 → May 8, 2020 · 3 filings
  • May 8, 2020 · D · $32,444,441 sold of $32,444,441 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • May 8, 2020 · D · $250,000,000 sold of $250,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 29, 2018 · D · $66,000,000 sold of Indefinite · 5 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $250M from 5 investors (100% of the $32.4M target) as of the latest filing. Robert is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

G
Biotechnology

GRAIL, Inc.

Menlo Park, CA · Mar 14, 2017 → May 7, 2020 · 7 filings
  • May 7, 2020 · D/A · $388,407,514 sold of $425,000,000 · 14 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 12, 2019 · D · $125,000,000 sold of $250,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • May 25, 2018 · D · $300,000,000 sold of Indefinite · 14 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jan 11, 2018 · D/A · $1,214,655,040 sold of Indefinite · 59 investors · min. No minimum reported · role: Director EDGAR ↗
  • Nov 22, 2017 · D/A · $1,211,655,039 sold of Indefinite · 58 investors · min. No minimum reported · role: Director EDGAR ↗
  • Apr 26, 2017 · D/A · $973,248,965 sold of Indefinite · 47 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 14, 2017 · D · $914,024,940 sold of Indefinite · 27 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $1.21B from 59 investors (100% of the $425M target) as of the latest filing. Robert is listed as director on 7 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AV
Pooled Investment Fund · group: Arch Venture

ARCH Venture Fund X Overage, L.P.

Chicago, IL · Oct 26, 2018 → Oct 25, 2019 · 2 filings
  • Oct 25, 2019 · D/A · $635,750,000 sold of $675,000,000 · 68 investors · min. No minimum reported · role: Executive Officer (Managing Director of the GP LLC) EDGAR ↗
  • Oct 26, 2018 · D · $0 sold of $600,000,000 · 0 investors · min. No minimum reported · role: Executive Officer (Managing Director of the GP LLC) EDGAR ↗

Raised $635.8M from 68 investors (94% of the $675M target) as of the latest filing. Robert is listed as executive officer on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AV
Pooled Investment Fund · group: Arch Venture

ARCH Venture Fund X, L.P.

Chicago, IL · Oct 26, 2018 → Oct 25, 2019 · 2 filings
  • Oct 25, 2019 · D/A · $635,750,000 sold of $675,000,000 · 69 investors · min. No minimum reported · role: Executive Officer (Managing Director of the GP LLC) EDGAR ↗
  • Oct 26, 2018 · D · $0 sold of $600,000,000 · 0 investors · min. No minimum reported · role: Executive Officer (Managing Director of the GP LLC) EDGAR ↗

Raised $635.8M from 69 investors (94% of the $675M target) as of the latest filing. Robert is listed as executive officer on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

BT
Pharmaceuticals

Beam Therapeutics Inc.

Cambridge, MA · Mar 26, 2019 → Mar 26, 2019 · 2 filings
  • Mar 26, 2019 · D · $135,000,002 sold of $135,000,002 · 27 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 26, 2019 · D/A · $83,573,967 sold of $83,573,967 · 21 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $135M from 27 investors (100% of the $135M target) as of the latest filing. Robert is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

GB
Biotechnology

Gossamer Bio, Inc.

San Diego, CA · Jan 19, 2018 → Aug 1, 2018 · 3 filings
  • Aug 1, 2018 · D · $230,015,000 sold of $230,015,000 · 67 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jan 19, 2018 · D · $70,468,084 sold of $80,000,000 · 3 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jan 19, 2018 · D · $70,468,084 sold of $80,000,000 · 3 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $230M from 70 investors (100% of the $230M target) as of the latest filing. Robert is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

UB
Pharmaceuticals

Unity Biotechnology, Inc.

Brisbane, CA · May 5, 2009 → Mar 27, 2018 · 6 filings
  • Mar 27, 2018 · D · $55,049,948 sold of $60,000,000 · 27 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 21, 2017 · D/A · $151,230,099 sold of $177,598,051 · 38 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 1, 2016 · D · $108,320,117 sold of $128,278,051 · 26 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 15, 2013 · D · $2,041,555 sold of $6,083,265 · 4 investors · min. No minimum reported · role: Director EDGAR ↗
  • May 5, 2009 · D · $250,000 sold of $1,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • May 5, 2009 · D · $500 sold of $500 · 2 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $151.2M from 38 investors (100% of the $60M target) as of the latest filing. Robert is listed as director on 6 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

SP
Biotechnology

Syros Pharmaceuticals, Inc.

Cambridge, MA · Apr 22, 2013 → Feb 9, 2018 · 4 filings
  • Feb 9, 2018 · D/A · $11,380,018 sold of $11,380,018 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jan 17, 2018 · D · $9,999,995 sold of $9,999,995 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Oct 24, 2014 · D · $53,149,996 sold of $53,149,996 · 16 investors · min. No minimum reported · role: Director EDGAR ↗
  • Apr 22, 2013 · D · $10,000,000 sold of $12,000,000 · 3 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $129.8M from 19 investors (100% of the $11.4M target) as of the latest filing. Robert is listed as director on 4 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

JT
Biotechnology

Juno Therapeutics, Inc.

Seattle, WA · Dec 26, 2013 → Oct 5, 2017 · 7 filings
  • Oct 5, 2017 · D · $31,091,407 sold of $31,091,407 · 1 investors · min. No minimum reported · role: Director, Promoter EDGAR ↗
  • Jun 29, 2017 · D/A · $898,495,324 sold of Indefinite · 2 investors · min. No minimum reported · role: Director, Promoter EDGAR ↗
  • Jul 6, 2016 · D/A · $896,803,493 sold of Indefinite · 2 investors · min. No minimum reported · role: Director, Promoter EDGAR ↗
  • Jul 14, 2015 · D · $849,803,496 sold of Indefinite · 1 investors · min. No minimum reported · role: Director, Promoter EDGAR ↗
  • Aug 14, 2014 · D · $85,499,985 sold of $133,734,641 · 22 investors · min. No minimum reported · role: Director, Promoter EDGAR ↗
  • May 8, 2014 · D · $28,423,971 sold of $97,000,000 · 34 investors · min. No minimum reported · role: Director, Promoter EDGAR ↗
  • Dec 26, 2013 · D · $6,667,672 sold of $7,145,909 · 21 investors · min. No minimum reported · role: Director, Promoter EDGAR ↗

Raised $898.5M from 34 investors (100% of the $31.1M target) as of the latest filing. Robert is listed as director, promoter on 7 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(c) (163 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

A
Other Health Care · group: Maveron

Arivale Inc.

Seattle, WA · Jun 13, 2017
  • Jun 13, 2017 · D · $13,600,004 sold of $29,999,999 · 9 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $17M from 9 investors (57% of the $30M target) as of the latest filing. Robert is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

SB
Biotechnology

Sienna Biopharmaceuticals, Inc.

Weslake Village, CA · May 15, 2017 → May 15, 2017 · 2 filings
  • May 15, 2017 · D · $40,471,910 sold of $40,500,000 · 29 investors · min. No minimum reported · role: Director EDGAR ↗
  • May 15, 2017 · D/A · $46,630,453 sold of $50,000,000 · 91 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $46.6M from 91 investors (100% of the $40.5M target) as of the latest filing. Robert is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AV
Pooled Investment Fund · group: Arch Venture

ARCH Venture Fund IX Overage, L.P.

Chicago, IL · Nov 18, 2016
  • Nov 18, 2016 · D · $0 sold of $450,000,000 · 0 investors · min. No minimum reported · role: Executive Officer (Managing Director of the GP LLC) EDGAR ↗

No sales reported yet as of the latest filing. Robert is listed as executive officer.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AV
Pooled Investment Fund · group: Arch Venture

ARCH Venture Fund IX, L.P.

Chicago, IL · Mar 17, 2016 → Nov 18, 2016 · 2 filings
  • Nov 18, 2016 · D/A · $408,385,714 sold of $550,000,000 · 19 investors · min. No minimum reported · role: Executive Officer (Managing Director of the GP LLC) EDGAR ↗
  • Mar 17, 2016 · D · $0 sold of $400,000,000 · 0 investors · min. No minimum reported · role: Executive Officer (Managing Director of the GP LLC) EDGAR ↗

Raised $408.4M from 19 investors (74% of the $550M target) as of the latest filing. Robert is listed as executive officer on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

SE
Other Energy

SAPPHIRE ENERGY, INC.

San Diego, CA · Dec 15, 2015
  • Dec 15, 2015 · D · $91,963,851 sold of $91,963,851 · 16 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $92M from 16 investors (100% of the $92M target) as of the latest filing. Robert is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Energy / 506(b) (1,000 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AV
Pooled Investment Fund · group: Arch Venture

ARCH Venture Fund VIII Overage, L.P.

Chicago, IL · Mar 6, 2015
  • Mar 6, 2015 · D · $0 sold of $150,000,000 · 0 investors · min. No minimum reported · role: Executive Officer (Managing Director of the General Partner.) EDGAR ↗

No sales reported yet as of the latest filing. Robert is listed as executive officer.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AV
Pooled Investment Fund · group: Arch Venture

ARCH Venture Fund VIII, L.P.

Chicago, IL · Apr 24, 2014 → Aug 27, 2014 · 2 filings
  • Aug 27, 2014 · D/A · $400,532,000 sold of $400,532,000 · 20 investors · min. $250,000 · role: Executive Officer (Managing Director of the GP LLC.) EDGAR ↗
  • Apr 24, 2014 · D · $0 sold of $250,000,000 · 0 investors · min. No minimum reported · role: Executive Officer (Managing Director of the GP LLC.) EDGAR ↗

Raised $400.5M from 20 investors (100% of the $400.5M target) as of the latest filing. Robert is listed as executive officer on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

FP
Other

Faraday Pharmaceuticals, Inc.

Seattle, WA · Jul 23, 2014
  • Jul 23, 2014 · D · $3,657,274 sold of $6,507,274 · 4 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $52.8M from 11 investors (100% of the $6.51M target) as of the latest filing. Robert is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other / 506(b) (18,678 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

BT
Pharmaceuticals

Bellerophon Therapeutics, Inc.

Warren, NJ · Feb 21, 2014 → Jul 2, 2014 · 2 filings
  • Jul 2, 2014 · D · $1 sold of $1 · 6 investors · min. No minimum reported · role: Director EDGAR ↗
  • Feb 21, 2014 · D · $1 sold of $1 · 4 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $23.4M from 11 investors (100% of the $1 target) as of the latest filing. Robert is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

ST
Other Health Care

Sage Therapeutics, Inc.

Cambridge, MA · Jan 21, 2014 → Mar 24, 2014 · 2 filings
  • Mar 24, 2014 · D · $38,000,000 sold of $38,000,000 · 15 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jan 21, 2014 · D · $10,000,000 sold of $20,000,000 · 3 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $650M from 15 investors (100% of the $38M target) as of the latest filing. Robert is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

FT
Biotechnology

FATE THERAPEUTICS INC

San Diego, CA · Nov 23, 2009 → Aug 13, 2013 · 6 filings
  • Aug 13, 2013 · D · $20,000,000 sold of $20,000,000 · 3 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 21, 2012 · D · $9,244,679 sold of Indefinite · 17 investors · min. No minimum reported · role: Director EDGAR ↗
  • Apr 20, 2011 · D · $1,000,000 sold of $1,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Apr 20, 2011 · D/A · $35,988,360 sold of $35,988,360 · 18 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 24, 2009 · D/A · $32,488,360 sold of $32,488,360 · 16 investors · min. No minimum reported · role: Director EDGAR ↗
  • Nov 23, 2009 · D · $30,488,360 sold of $30,488,360 · 16 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $56.7M from 21 investors (100% of the $20M target) as of the latest filing. Robert is listed as director on 6 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

N
Pharmaceuticals

NeurogesX Inc

San Mateo, CA · Aug 3, 2011 → Nov 27, 2012 · 5 filings
  • Nov 27, 2012 · D · $684,300 sold of $684,300 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 29, 2012 · D · $975,000 sold of $975,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Feb 8, 2012 · D · $2,999,382 sold of $2,999,382 · 6 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 17, 2011 · D · $1,425,000 sold of $1,425,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 3, 2011 · D · $20,209,229 sold of $20,209,229 · 29 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $20.2M from 29 investors (100% of the $684K target) as of the latest filing. Robert is listed as director on 5 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

AP
Pharmaceuticals

AGIOS PHARMACEUTICALS INC

Cambridge, MA · Apr 26, 2010 → Nov 22, 2011 · 2 filings
  • Nov 22, 2011 · D · $78,000,001 sold of $78,000,001 · 19 investors · min. No minimum reported · role: Director EDGAR ↗
  • Apr 26, 2010 · D · $8,823,937 sold of $8,823,937 · 1 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $78M from 19 investors (100% of the $78M target) as of the latest filing. Robert is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

KB
Pharmaceuticals

KYTHERA BIOPHARMACEUTICALS INC

Calabasas, CA · Sep 15, 2011
  • Sep 15, 2011 · D · $37,424,989 sold of $52,424,997 · 20 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $37.4M from 20 investors (71% of the $52.4M target) as of the latest filing. Robert is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

KE
Other Technology

Kilimanjaro Energy, Inc.

Waukesha, WI · Aug 6, 2010 → Aug 6, 2010 · 2 filings
  • Aug 6, 2010 · D · $2,250,000 sold of $2,250,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 6, 2010 · D · $900,000 sold of $5,000,000 · 2 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $2.25M from 2 investors (100% of the $2.25M target) as of the latest filing. Robert is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

R
Pharmaceuticals

Receptos, Inc.

San Diego, CA · Nov 23, 2009
  • Nov 23, 2009 · D · $11,999,999 sold of $20,024,000 · 6 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $12M from 14 investors (60% of the $20M target) as of the latest filing. Robert is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

IH
Pharmaceuticals

IKARIA HOLDINGS INC

Clinton, NJ · Oct 2, 2009
  • Oct 2, 2009 · D/A · $54,947,203 sold of Indefinite · 75 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $54.9M from 75 investors as of the latest filing. Robert is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

Other pages with the same name (1)

Separate person records under the same name, not combined with this page. Each line says whether it shares an issuer with this record.

  • Robert Nelsen — MN, 1 issuer, Oct 4, 2022 → Oct 4, 2022 · no shared issuer

People around Robert 40

Officers, directors, promoters and management entities named on the same filings, as of Oct 23, 2026, 5:45 PM ET. Showing the 40 with the most shared filings.

AV
Management entity

ARCH Venture Partners X, L.P.

Director · 4 shared filings (2 issuers)

Listed on the same filings as Robert Nelsen. Their page shows their other deals.

AV
Management entity

ARCH Venture Partners VIII, L.P.

Director · 3 shared filings (2 issuers)

Listed on the same filings as Robert Nelsen. Their page shows their other deals.

AV
Management entity

ARCH Venture Partners IX, L.P.

Director · 3 shared filings (2 issuers)

Listed on the same filings as Robert Nelsen. Their page shows their other deals.

AV
Management entity

ARCH Venture Partners XI, L.P.

Director · 2 shared filings (1 issuer)

Listed on the same filings as Robert Nelsen. Their page shows their other deals.

AV
Management entity

ARCH Venture Partners XII, L.P.

Director · 2 shared filings (1 issuer)

Listed on the same filings as Robert Nelsen. Their page shows their other deals.

AV
Management entity

ARCH Venture Partners XIV, L.P.

Director · 1 shared filing (1 issuer)

Listed on the same filings as Robert Nelsen. Their page shows their other deals.

KB
No photo found yet (own website and image search run after this page is viewed)
Person

Kristina Burow

Director, Executive Officer · 33 shared filings (17 issuers) · also on 15 other issuers

Kristina Burow is on 32 issuers in total — a repeat sponsor. Their page lists every one.

MM
No photo found yet (own website and image search run after this page is viewed)
Person

Mark McDonnell

Executive Officer · 16 shared filings (10 issuers) · also on 4 other issuers

Mark McDonnell is on 14 issuers in total — a repeat sponsor. Their page lists every one.

KC
No photo found yet (own website and image search run after this page is viewed)
Person

Keith Crandell

Executive Officer · 15 shared filings (9 issuers) · also on 7 other issuers

Keith Crandell is on 16 issuers in total — a repeat sponsor. Their page lists every one.

RK
No photo found yet (own website and image search run after this page is viewed)
Person

Richard Klausner

Director, Promoter · 13 shared filings (3 issuers) · also on 5 other issuers

Richard Klausner is on 8 issuers in total — a repeat sponsor. Their page lists every one.

SG
No photo found yet (own website and image search run after this page is viewed)
Person

Steven Gillis

Executive Officer, Director, Promoter · 11 shared filings (7 issuers) · also on 23 other issuers

Steven Gillis is on 30 issuers in total — a repeat sponsor. Their page lists every one.

HB
No photo found yet (own website and image search run after this page is viewed)
Person

Hans Bishop

Executive Officer, Director, Promoter · 11 shared filings (3 issuers) · also on 2 other issuers

Hans Bishop is on 5 issuers in total — a repeat sponsor. Their page lists every one.

WR
No photo found yet (own website and image search run after this page is viewed)
Person

William Rastetter

Executive Officer, Director · 10 shared filings (3 issuers) · also on 1 other issuer

Listed on the same filings as Robert Nelsen. Their page shows their other deals.

ND
No photo found yet (own website and image search run after this page is viewed)
Person

Nathaniel David

Executive Officer, Director · 9 shared filings (3 issuers)

Listed on the same filings as Robert Nelsen. Their page shows their other deals.

AN
No photo found yet (own website and image search run after this page is viewed)
Person

Amir Nashat

Director · 8 shared filings (2 issuers) · also on 27 other issuers

Amir Nashat is on 29 issuers in total — a repeat sponsor. Their page lists every one.

BR
No photo found yet (own website and image search run after this page is viewed)
Person

Bryan Roberts

Director · 8 shared filings (3 issuers) · also on 29 other issuers

Bryan Roberts is on 32 issuers in total — a repeat sponsor. Their page lists every one.

HP
No photo found yet (own website and image search run after this page is viewed)
Person

Howard Pien

Director · 8 shared filings (2 issuers)

Listed on the same filings as Robert Nelsen. Their page shows their other deals.

PT
No photo found yet (own website and image search run after this page is viewed)
Person

Paul Thurk

Executive Officer · 8 shared filings (5 issuers)

Paul Thurk is on 5 issuers in total — a repeat sponsor. Their page lists every one.

JH
No photo found yet (own website and image search run after this page is viewed)
Person

Jeffrey T. Huber

Executive Officer, Director · 7 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Robert Nelsen. Their page shows their other deals.

SH
No photo found yet (own website and image search run after this page is viewed)
Person

Steven Harr

Executive Officer, Director · 7 shared filings (2 issuers)

Listed on the same filings as Robert Nelsen. Their page shows their other deals.

KL
No photo found yet (own website and image search run after this page is viewed)
Person

Keith Leonard

Executive Officer, Director · 6 shared filings (3 issuers) · also on 2 other issuers

Keith Leonard is on 5 issuers in total — a repeat sponsor. Their page lists every one.

CW
No photo found yet (own website and image search run after this page is viewed)
Person

Carl Weissman

Director · 6 shared filings (1 issuer) · also on 7 other issuers

Carl Weissman is on 8 issuers in total — a repeat sponsor. Their page lists every one.

VS
No photo found yet (own website and image search run after this page is viewed)
Person

Vicki Sato

Director · 6 shared filings (2 issuers) · also on 4 other issuers

Vicki Sato is on 6 issuers in total — a repeat sponsor. Their page lists every one.

CB
No photo found yet (own website and image search run after this page is viewed)
Person

Clinton W. Bybee

Executive Officer · 6 shared filings (4 issuers) · also on 3 other issuers

Clinton W. Bybee is on 7 issuers in total — a repeat sponsor. Their page lists every one.

HB
No photo found yet (own website and image search run after this page is viewed)
Person

Hal V Barron

Director · 6 shared filings (2 issuers) · also on 1 other issuer

Listed on the same filings as Robert Nelsen. Their page shows their other deals.

SW
No photo found yet (own website and image search run after this page is viewed)
Person

Scott Wolchko

Executive Officer · 6 shared filings (1 issuer)

Listed on the same filings as Robert Nelsen. Their page shows their other deals.

JM
No photo found yet (own website and image search run after this page is viewed)
Person

John Mendlein

Executive Officer, Director · 6 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as Robert Nelsen. Their page shows their other deals.

AE
No photo found yet (own website and image search run after this page is viewed)
Person

Anthony Evnin

Director · 6 shared filings (1 issuer)

Listed on the same filings as Robert Nelsen. Their page shows their other deals.

MW
No photo found yet (own website and image search run after this page is viewed)
Person

Mary Agnes Wilderotter

Director · 6 shared filings (2 issuers)

Listed on the same filings as Robert Nelsen. Their page shows their other deals.

JD
No photo found yet (own website and image search run after this page is viewed)
Person

Jason Doren

Executive Officer · 6 shared filings (4 issuers)

Listed on the same filings as Robert Nelsen. Their page shows their other deals.

MC
No photo found yet (own website and image search run after this page is viewed)
Person

Min Cui

Director · 5 shared filings (1 issuer) · also on 4 other issuers

Min Cui is on 5 issuers in total — a repeat sponsor. Their page lists every one.

AD
No photo found yet (own website and image search run after this page is viewed)
Person

Anthony DiTonno

Executive Officer, Director · 5 shared filings (1 issuer) · also on 3 other issuers

Listed on the same filings as Robert Nelsen. Their page shows their other deals.

SG
No photo found yet (own website and image search run after this page is viewed)
Person

Stephen F. Ghiglieri

Executive Officer · 5 shared filings (1 issuer)

Listed on the same filings as Robert Nelsen. Their page shows their other deals.

GL
No photo found yet (own website and image search run after this page is viewed)
Person

Gary Lyons

Director · 5 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as Robert Nelsen. Their page shows their other deals.

JO
No photo found yet (own website and image search run after this page is viewed)
Person

John Orwin

Director · 5 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as Robert Nelsen. Their page shows their other deals.

SN
No photo found yet (own website and image search run after this page is viewed)
Person

Steven Nelson

Director · 5 shared filings (1 issuer)

Listed on the same filings as Robert Nelsen. Their page shows their other deals.

BG
No photo found yet (own website and image search run after this page is viewed)
Person

Bradford Goodwin

Director · 5 shared filings (1 issuer)

Listed on the same filings as Robert Nelsen. Their page shows their other deals.

The team behind the deals

AV
Sponsor group

Arch Venture

10 issuers · 16 filings · $6.74B reported sold · 2014–2026

One team, 10 deal companies. Robert Nelsen is listed on 10 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Robert Nelsen.

M
Sponsor group

Maveron

16 issuers · 24 filings · $544.5M reported sold · 2013–2022

One team, 16 deal companies. Robert Nelsen is listed on 1 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Robert Nelsen.

Same business address

51 other issuers file from the same address (first 50 shown)

A shared address can mean the same team, a shared office building or a registered agent. It is a lead, not a conclusion.

Registrations and other filings

Adviser registration (Form ADV)

None of the 39 issuers this person is listed on appears in Form ADV (searched 24,962 advisers as of Oct 2, 2026). A person is never an adviser firm; Form ADV is checked for the issuers and the management companies they are listed with.

Other offering types (Regulation A and Regulation Crowdfunding)

Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.

Property records none — individuals are not matched

Property records are matched to companies only, never to individuals, so none are matched to Robert Nelsen by design. Searched property records in Hillsborough County FL (Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026 + FL DOR 2026 ownership roll), Miami-Dade County FL (FL DOR 2026 ownership roll), Harris County TX (HCAD 2026 ownership roll), Dallas County TX (DCAD 2026 ownership roll), New York City ACRIS documents and PLUTO ownership rows already retrieved for other issuers, Cook County IL sale and ownership rows already retrieved for other issuers (814,874 records as of Oct 23, 2026, 8:59 PM ET) for the 39 issuers this person is listed on — nothing matched.

Public profiles and social

Websites and social links of the issuers Robert Nelsen is listed on: none on file. No website or social profile named in GRAIL, Inc.'s SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #55,431 of 374,652 in line (48 issuers searched so far). One-tap searches: Look further ↓

Look further

One-tap searches on sites we do not index ourselves, with the name pre-filled (Menlo Park, CA). Each opens in a new tab; what you find there is not verified by PartnerFacts.

Social and web

LinkedIn people search ↗Instagram ↗X (Twitter) ↗Facebook ↗YouTube ↗Google ↗Google Images ↗Google News ↗Meta Ad Library ↗

Courts

CourtListener / RECAP (federal) ↗PACER case locator (federal, login) ↗Washington Courts case search (dw.courts.wa.gov) ↗Cook County Clerk of Court case search ↗New Jersey state courts — find the court ↗Massachusetts MassCourts ↗California — find the county court ↗Los Angeles Superior Court case search ↗New York WebCivil Supreme ↗Colorado state courts — find the court ↗Wisconsin state courts — find the court ↗

Securities regulators

SEC EDGAR full-text search ↗SEC action look-up ↗FINRA BrokerCheck ↗SEC IAPD adviser search ↗

Business registries

Washington Secretary of State business search ↗Illinois Secretary of State business search ↗New Jersey Secretary of State business search ↗Massachusetts Secretary of State business search ↗California Secretary of State business search ↗New York Secretary of State business search ↗Colorado Secretary of State business search ↗Wisconsin Secretary of State business search ↗OpenCorporates ↗

Change history

No corrections have been requested for this page.

Every fact links to its public-record source. Plain-English notes next to a fact are our reading of that fact, not a rating. Request a correction · Facts policy

Request a correction

Free. Logged with status: received → under review → fixed / confirmed with source.

Add a response

If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.

Monitor this person

Members get an email when Robert Nelsen appears on a new Form D, or when a court case or SEC action is matched to them. See plans →